Abstract

Objective: To describe a patient with a perfused CRVO that responded to intravitreal aflibercept after prior treatment with intravitreal bevacizumab and intravitreal ranibizumab.

Design: Retrospective report of a case.

Methods: Institutional retrospective review of a single case of a patient with CRVO-related macular edema treated with anti-VEGF agents (bevacizumab, ranibizumab and aflibercept). Baseline demographics, visual acuity and OCT scans are reported.

Results: A 62 year old male with a perfused CRVO with marked cystoid macular edema was treated with intravitreal aflibercept and subsequently experienced significant improvement in visual acuity and central foveal thickness. This effect was observed despite prior treatment with intravitreal bevacizumab as well as intravitreal ranibizumab.

Conclusion: Intravitreal aflibercept is a viable treatment option for macular edema due to CRVO in eyes even after prior treatment with other anti-VEGF agents.

Keywords: CRVO, bevacizumab, ranibizumab, aflibercept, VEGF, macular edema